[go: up one dir, main page]

PE20080195A1 - Formas cristalinas de un compuesto de dimetilfenilo - Google Patents

Formas cristalinas de un compuesto de dimetilfenilo

Info

Publication number
PE20080195A1
PE20080195A1 PE2007000508A PE2007000508A PE20080195A1 PE 20080195 A1 PE20080195 A1 PE 20080195A1 PE 2007000508 A PE2007000508 A PE 2007000508A PE 2007000508 A PE2007000508 A PE 2007000508A PE 20080195 A1 PE20080195 A1 PE 20080195A1
Authority
PE
Peru
Prior art keywords
compound
crystalline forms
dimethylphenyl compound
dimethylphenylcarbamoil
betha2
Prior art date
Application number
PE2007000508A
Other languages
English (en)
Inventor
Jennifer Bolton
Robert Chao
Miroslaw Rapta
Lisa Williams
Richard D Wilson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of PE20080195A1 publication Critical patent/PE20080195A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN COMPUESTO QUE ES UNA BASE LIBRE CRISTALINA DEL ESTER 1-[2(4-{[(R)-2-(3-FORMILAMINO-4-HIDROXIFENIL)-2-HIDROXIETILAMINO]METIL}-2,5-DIMETILFENILCARBAMOIL)ETIL]PIPERIDIN-4-ILICO DEL ACIDO BIFENIL-2-ILCARBAMICO CARACTERIZADA POR UN PATRON DE RAYOS X SOBRE POLVO CON PICOS DE DIFRACCION EN VALORES 2TETHA 17,7 +-0,3; 18,2+-0,3; 23,2+-0,3 Y UNA GRAFICA DE CALORIMETRIA DIFERENCIAL DE BARRIDO QUE MAXIMO EN EL FLUJO DE CALOR ENDOTERMICO DENTRO DEL RANGO ENTRE 142 C-150 C. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE ADEMAS UN AGENTE ANTIINFLAMATORIO ESTEROIDE. DICHO COMPUESTO ES AGONISTA DEL RECEPTOR BETHA2 ADRENERGICO UTIL EN EL TRATAMIENTO DE UN TRASTORNO PULMONAR
PE2007000508A 2006-04-25 2007-04-24 Formas cristalinas de un compuesto de dimetilfenilo PE20080195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79470906P 2006-04-25 2006-04-25

Publications (1)

Publication Number Publication Date
PE20080195A1 true PE20080195A1 (es) 2008-04-04

Family

ID=38556280

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000508A PE20080195A1 (es) 2006-04-25 2007-04-24 Formas cristalinas de un compuesto de dimetilfenilo

Country Status (10)

Country Link
US (2) US7880010B2 (es)
EP (1) EP2010490B1 (es)
JP (1) JP2009535340A (es)
CN (1) CN101426765A (es)
AR (1) AR060648A1 (es)
AT (1) ATE520660T1 (es)
CA (1) CA2650631A1 (es)
PE (1) PE20080195A1 (es)
TW (1) TW200811104A (es)
WO (1) WO2007127297A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
US7278982B2 (en) 2003-03-27 2007-10-09 Bioactis Limited Powder medicine applicator for nasal cavity
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
US20090216010A1 (en) * 2008-02-22 2009-08-27 Wei-Hong Tseng Crystalline carbapenem compound and produced method thereof
SG175023A1 (en) * 2009-04-14 2011-11-28 Glaxo Group Ltd Process for the preparation of a biphenyl-2-ylcarbamic acid ester
ES2635358T3 (es) 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2014175234A1 (ja) * 2013-04-26 2014-10-30 富士フイルム株式会社 撮像装置及び画像表示方法
CN107108502A (zh) * 2015-05-14 2017-08-29 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004101525A1 (en) * 2003-05-08 2004-11-25 Theravance, Inc. Crystalline form of aryl aniline beta-2 adrenergic receptor agonist
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
EP1833822A2 (en) * 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
US7558576B2 (en) * 2005-03-29 2009-07-07 Qualcomm Incorporated Employing frequency offset to compensate for Doppler shift
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
TW200811104A (en) 2008-03-01
CN101426765A (zh) 2009-05-06
US20110086881A1 (en) 2011-04-14
US7880010B2 (en) 2011-02-01
JP2009535340A (ja) 2009-10-01
EP2010490B1 (en) 2011-08-17
CA2650631A1 (en) 2007-11-08
EP2010490A2 (en) 2009-01-07
AR060648A1 (es) 2008-07-02
US20070249674A1 (en) 2007-10-25
WO2007127297A2 (en) 2007-11-08
ATE520660T1 (de) 2011-09-15
WO2007127297A3 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
PE20080195A1 (es) Formas cristalinas de un compuesto de dimetilfenilo
CL2020002010A1 (es) Uso de un polipéptido que comprende una hormona de crecimiento, y ctps adheridos a la misma, para inducir crecimiento o ganancia de peso. (divisional solicitud 201400254)
PE20140252A1 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf
ES2575666T3 (es) Proceso de fabricación de un agente farmacéuticamente activo
UY33397A (es) Forma sólida de un naftaleno carboxamida
ECSP088106A (es) Formas de dosificación de liberación retardada oral altamente biodisponible del succinato de o-desmetilvenlafaxina
ATE542248T1 (de) Elektrolumineszenz-gerät
BRPI0606318A2 (pt) composto, composição, e, uso de um composto
AR061481A1 (es) Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a
PE20120812A1 (es) Compuestos vinil indazolilo
BRPI0514474A (pt) multiparticulados
PE20081175A1 (es) Derivados de ftalazinona
ES2342489T3 (es) Procedimiento para producir una pila de combustible de oxido solido reversible.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CL2011003264A1 (es) Forma cristalina i de 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropil-amino]butiloxi}-n-(metilsulfonil)acetamida, agonista del receptor de pgi2; metodo de preparacion, composicion farmaceutica, y uso para el tratamiento de hipertension, trombosis, nefropatia diabetica, asma bronquial, ulcera, entre otras.
AR077416A2 (es) Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos
NO20083426L (no) IPBC-inneholdene koacervater
CL2007003580A1 (es) Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes.
EP2571486A4 (en) DRY POWDER INHALATION COMPOSITION
PE20120105A1 (es) Combinaciones farmaceuticas que comprenden refametinib
AR043968A1 (es) Oxido nitrico en el tratamiento de inflamacion
PE20060174A1 (es) Nuevos compuestos alquinicos con actividad antagonista de mch y medicamentos que contienen estos compuestos
AR068845A1 (es) Composicion farmaceutica que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-((1,3,4-oxadiazol-2-il))fenil)piridin-3-sulfonamida util para el tratamiento del cancer
UY27727A1 (es) Nueva composicion farmacéutica-
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten

Legal Events

Date Code Title Description
FD Application declared void or lapsed